Technetium

Summary

Technetium (CHEMBL1201315) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201315
Name	Technetium
Type	Small molecule
Max phase	3

Also known as: Technetium, TECHNETIUM

Parent form; salt/anhydrous children: CHEMBL4297443

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE4	6
Not specified	6
PHASE1	3
PHASE2	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00162331	PHASE4	COMPLETED	CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI
NCT00162344	PHASE4	COMPLETED	A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary Disease.
NCT00162357	PHASE4	COMPLETED	Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
NCT00381316	PHASE4	COMPLETED	Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches
NCT01495377	PHASE4	COMPLETED	Opioid Induced Swallowing Difficulties and Risk for Pulmonary Aspiration
NCT02612870	PHASE4	UNKNOWN	Sienna+® Injection Time Study 4 Arms
NCT00826280	PHASE3	COMPLETED	Caffeine’s Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
NCT07107633	PHASE2	RECRUITING	A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
NCT00162045	PHASE1/PHASE2	COMPLETED	A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects
NCT01334918	PHASE2	COMPLETED	A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
NCT07446647	PHASE1	RECRUITING	Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion
NCT00864110	PHASE1	COMPLETED	Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT06443710	PHASE1	COMPLETED	Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers
NCT07441733	Not specified	RECRUITING	Evaluate the Implementation of Using Indocyanine Green for Sentinel Lymph Node Mapping in Breast Cancer Patients
NCT00541190	Not specified	COMPLETED	Absorptive Clearance in the Cystic Fibrosis Airway
NCT01982123	Not specified	COMPLETED	SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy
NCT02336737	Not specified	COMPLETED	SentiMag® Intraoperative Comparison in Breast Cancer
NCT03109262	Not specified	COMPLETED	Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors
NCT05717205	Not specified	UNKNOWN	Pathophysiology of Diabetic Gastroparesis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).